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Abstract 
The frequency of hepatitis C vi­
rus (HCV) infection in Mosul was 
assessed by mean of a recombinent­
based immunoassay for serum anti­
HCVantibody. 
Serum samples from 14848 
blood donors, 213 health-care work­
ers, 543 actuely-ill patients suspected 
clinically of having viral hepatitis, 
173 thalassemic patients, and 107 
kidney patients were tested for the 
presence of anti-HCV by enzyme 
linked immunosorbent assay 
(ELISA). 
Anti-HCV antibodies were de­
tected in 0.64 blood donors, 
0.47% health-care workers, 2.58% 
acutely ill-patients, but in 37.0% of 
the thalassemic patients and 40.2% 
of renal dialysis unit patients. 
Introduction 
Until relatively recently, it was 
believed that hepatitis B virus (HBV) 
and hepatitis A virus (HAV) were 
the only forms of viral hepatitis. But 
on virological and immunological 
basis distinct agents have been shown 
to exist, including the delta agent, or 
hepatitis D (HDV). This is a defec­
tive yirus requiring the hepatitis B 
virus to be present for its replication 
and expression(1J. . 
On clinical and epidemiological 
basis, it has become clear that more 
than infections agent is responsible 
for non-A, non-B hepatitis 
(NANBH), so named becaus of the 
absence of serologic markers for 
hepatitis A or B in clinically diag­
nosed cases of heptitis. A virus asso­
ciated with parentral transmission of 
NANBH has been classified as hepa­
titis C (HCV) and a form of hepatitis 
spread entreically and previously 
known as epidemic or water-born 
NANBH , is now known as hepatitis 
E (HEV)(2,3). 
Most of the studies conducted 
until this time in Iraq have dealt with 
hepatitis B. This is justified on the 
light of the bad consequences such as 
liver liver cirrhosis and hepatoma 
this virus may have on some persons 
carrying it( 4,5). 
Infection with HA V, on the oth­
er hand, seems to be distributed 
thoughout the world mainly through 
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faecal-oral route, without prodduc­
ing a carrier state nor is it associated 
with those bad consequences as those 
found in HBY infection(6,7). The in­
cidence of HAY infection varies. In 
America anti-HAY was found in 
44% ,a rate which increased with 
age and low age and socioeconomic 
standerd .in the mediterranean cou­
tries the prevalence rate of anti-HAY 
was detected to be between 80­
90%(9). In Iraq(Baghdad) an anti­
HAY of 97 % was detected in the 
normal population (10). 
As far as HBY infection is con­
cerned Iraq is considered a country 
of medium endemicity rate(10,l1,12). 
Anti-HBs seroposivitity has been 
found to be up to 30.3% in the nor­
mal population(lO) and HBsAg prev­
alence rate ranged between 3.6­
5.9(10,12,13,14). Similar and higher 
figures have been found to occur in 
other parts of the middle east re­
garding the prevalence of HBsAg; 
highest being found in Saudi Arabia 
(9.5%) and Turkey (9.2%)(15). 
Studies, in some parts of the 
world have found that HCY infection 
traces HBY infection, more or less, 
in its mode of transmission and its 
future consequences, on the carrier 
persons(l6,17,18,19). Yet this infec­
tion has not been studied adequately 
in Iraq. This is because there has 
been' no reliable method for testing 
the direct markers of this virus in 
persons suspected of being infected 
with it. But recently a recombinent 
immunoassay has been described 
which could detects anti-HCY anti­
body in persons infected with this 
virus(3·2l). Using this method it was 
thought appropriate to initiate a 
work that studies the extennt of HCY 
infection and to find out its most 
probable routes of transmission in 
Mosul, using different groups of 
persons. 
Materials and Methods 
1- Persons tested: 
This study was conducted on 
five groups of persons, males and 
females as is shown in Table-l-, 
where two groups were of other­
wise healthy persons including 
14648 blood donors and 213 health­
car personnel (nurses and ward­
dressers). The other three groups 
were of ill persons including 173 
thalassemic children, 107 kidney pa­
tients, who attended renal dialysis 
unit for routine management, and 
543 clinically acute-ill patients sus­
pected by their physicians of having 
viral happatitis. The age rang and 
mean age and the share of each sex 
in each group was as seen in Table­
1-. 
2-Sera: 
Five-ml blood sample was 
drawn from each person in seperate 
test tube containing no anti­
coagulant. Each sample was either 
centrifuged and the serum was tested 
for anti-HCY, by ELISA, on the day 
or kept at 4°C for over night to 
settle and then its serum was tested 
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for the presence of anti-HCV as de­
scribed. 
3- Test for anti-Hey: 
For testing serum samples for 
the presence of anti-HCV the quantit­
ative enzyme immuonoassay manfac­
tured by United Biomedical Inc. 
USA abbreviated by (UBI HCV EIA) 
batch no. BJ00507, expiry date 5/97 
was used: 
This method is the same as the 
ones described by Choo et. ai. and 
Kuo et. al.(3.21) and was done as fol­
lows: using 10 ml of serum samples 
and both negative and positive con­
trols in each run. Each well in the 
microtitre plate containing 200ul of 
sample diluent so as to give a final 
dilution of 1 :21 in each well. Each 
initially reactive specimen was retest­
ed in duplicate. Specimens which did 
not react in either of the duplicate 
repeat tests were considered non­
reactive for antibodies to HCV. Ini­
tially reactive specimens which were 
reactive in one or both of the repeat­
ed test were considered repeatedly 
reactive for antibodies to HCV as as­
signed by the manufacturer. 
Results 
The results obtained in this 
study are summarised in Tables-l 
and -2-. 
Table-1- shows the details of the 
groups of persons included in this 
study with their sexes and the age 
range (and its nlean) in years for 
each group. The Table also shows 
the number of positive sera for anti­
HCV in each sex in each group and 
the percent positivity in each case. 
No. difference in the frequency of 
anti-HCV detected was noted in ei­
ther sex in all groups. 
Table-2- shows the results of 
test of sera, by ELISA, of different 
groups of persons for the presence 
of anti-HCV in MosuL This Table 
shows that higher frequency of anti­
HCV was detected in thalassemic pa­
tients and in kidney patients; two 
groups that are at "high risk" of get­
ting infected with HCV. In other two 
groups; blood donors and health­
care workers the frequencies were 
rather low. In group of acute pa­
tients the frequency was considered 
within expected reasonable levels. 
Discussion 
The frequency of HCV infec­
tion in blood donors as found in this 
study in Mosul, although it seems 
low (0.64%) yet on the light of the 
growing need of blood and blood 
products in general, this percentage 
can bulid-up into a substantial num­
ber, and on the other hand one can 
not neglect the importance of such 
route transmission. This is especialy 
true in patients who need multiple 
blood transfusion, e.g., thalassemic 
paticnts and patients attending renal 
dialysis unit. In these two groups of 
patients a very high incidence of 
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posItIve HCY infection rate was 
found in this study (37.0% and 
40.2% respectively). These two 
groups of patients are actually con­
sidered at "high-risk" because they 
get the virus transmitted to them 
straght into their blood circulation 
"­
when virus-contaminated blood is 
transfused to them as a result of 
their frequent need of it( 16). On the 
other hand, haemodialysis has been 
found to subject patients with renal 
failure to be carriers of HB V mark­
ers' due to immune deficiency, the 
cause of which is not fully under­
stood(l6). This could be happening in 
HCV infection in these two groups 
of patients in this study predisposing 
them to become carriers with mark­
ers of HCV as well. 
On the light of this finding in 
this study, it may be drawn that the 
most impoltant cause of transmission 
of HCV, at least here in J\10sul, is the 
l11ultitransfusion of blood. Such 
route of transmission has also been 
found regarding infection of HCV in 
other co~ntrie;(17.18.19). This could 
explain why the incidence of HCV in 
health-care workers as found in this 
study is comparatively low (0.47%), 
because this virus does not seem to 
be transmitted by casual contact but 
rather by repeated transfer of infect­
ed blood. 
In cases where acute hepatitis is 
suspected on clinical ground only, 
the percentage of HCY positive cases 
found in this study in J\10sul (2.58%) 
lies whithin accepted levels taking in 
mind that in this group of patients 
infection with another hepatitis vi­
rus, namely hepatitis B (HBV) has 
been found to be much higher here 
in Mosul(l2.22) and in Baghdad(lO). 
Contrary to infection with 
HBV(23.24), the frequency of detec­
tion of anti-HCY in either males and 
females was similar as found in this 
study (Table-l-) which could mean 
that the routeofinfection rather than 
sex is the prime determinant factor 
in getting infected with HCV. 
In conclusion it seems obligato­
ry that any person should have a test 
for HCV before blood donation. the 
use of a sensitive and reliable test as 
the one used here will facilitate the 
job thus limit the spread of this type 
of hepatitis virus. 
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Table (1) 

No. pf positives, Age range in No. 
group tested (% positivity)years (mean tested 
age In years 
91 (0.64)Blood Donors *M: 14238 
18 - 60 
(30) 4 (0.66) *F:610 
Health Workers 17 45 
 M:96 Nil (0.00) 
(27) 1 (0.85) F: 117 

Thalassemic Patients 35 (37.2) 1 17 
 M:94 
(7.6) 29 (36.6) F:79 
Acute-ill Patients 16 - 48 8(2.81)M:294I 

(31) 6(2.41)F: 249 

Kidney Patients 24(40.6)15 56 
 M:59 
(38) 19(39.5)F:48 
! 
I 

* M= M'ales , F = Females 
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Table (2) 

, 
group tested Number tested No. of positives Percent 
positivity(% ) 
Blood Donors 14848 95 0.64 
Health Workers 213 1 - .. 0.47 
Thalassemic Patient 173 64 37.0 
Acute-ill Patients 543 14 2.58 
Kidney Patients 107 43 40.2 
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